
    
      Subjects will be randomised in a 1:1 ratio to receive either CKD-701 or Lucentis®.
      Investigational Products (IP) (CKD-701 or Lucentis®) will be administered once a month during
      the loading phase(the first three months), and for the next nine months(PRN phase),
      administion will be determined based on the PRN administration criteria.
    
  